NCT06540326View on ClinicalTrials.gov

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer with Chemotherapy with Bevacizumab or Cetuximab

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

September 15, 2025

Study Completion Date

October 31, 2027

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

irinotecan liposome (II)

irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab

DRUG

fluorouracil

fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab

DRUG

cetuximab

cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil

DRUG

bevacizumab

bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil

Trial Locations (1)

Unknown

RECRUITING

The second affiliated hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER